ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

tenapanor

Also written as “Tenapanor”, “AZD1722” and “KHK7791”.

Its studies are mostly in Hyperphosphatemia · Constipation · Breast Feeding · Kidney Failure, Chronic · Renal Insufficiency, Chronic, led by 2 companies.

Drug pageTenapanor: every studyAll 37 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Jun 14, 201934 company-led studies, 2 open or runningNext primary completion: Feb 26, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Ardelyxits history only272 open or runningphase 4since Jun 14, 2019Apr 20, 2011Feb 26, 2027phase 3 · NCT07382167
Kyowa Kirin70 open or runningphase 3since Feb 16, 2021Jan 29, 2019none ahead

Also a collaborator on its studies: AstraZeneca.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Kyowa Kirin only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 29, 2019First study: phase 2 study in HyperphosphatemiaFirst studyNCT03831607 · 67 enrolled · Japan
  2. Mar 4, 20192 phase 2 studies in HyperphosphatemiaNCT03864458, NCT03864445
  3. Feb 16, 20214 phase 3 studies in HyperphosphatemiaNCT04771780, NCT04767581, NCT04766398 and 1 more

TargetBeta

SLC9A3 →read by rule
“Sodium/hydrogen exchanger 3 inhibitor”ChEMBL 37, by rule

Studies

All 7 Kyowa Kirin leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT04771780Hyperphosphatemia · Japan3CompletedJun 27, 2022213
NCT04767581Hyperphosphatemia · Japan3CompletedAug 10, 2021165
NCT04766398Hyperphosphatemia · Japan3CompletedSep 27, 2021169
NCT04766385Hyperphosphatemia · Japan3CompletedDec 1, 202154
NCT03864458Hyperphosphatemia · Japan2CompletedDec 10, 2019207
NCT03864445Hyperphosphatemia · Japan2CompletedDec 3, 201947
NCT03831607Hyperphosphatemia · Japan2CompletedNov 26, 201967

How it is read

Names in the registry

  • “Tenapanor”, 11 entries
  • “AZD1722”, 8 entries
  • “KHK7791”, 7 entries
  • “RDX5791”, 3 entries
  • “Tenapanor 50 MG”, 1 entry

Codes read as this program: AZD1722.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.